Current status of active surveillance in prostate cancer

Investigative and Clinical Urology

Volumn 57, Issue 1, 2016, Pages 14-20

  Chung, Mun Su ^a   Lee, Seung Hwan ^b  

^a Catholic Kwandong University   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Prostatectomy; Prostatic neoplasms; Watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; CLINICAL PROTOCOL; ETHNOLOGY; HEALTH SURVEY; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PROCEDURES; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA; WATCHFUL WAITING;

ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL PROTOCOLS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PATIENT SELECTION; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 84961653861     PISSN: 24660493     EISSN: 2466054X     Source Type: Journal    
DOI: 10.4111/icu.2016.57.1.14     Document Type: Review

References (54)

1. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439-43.
2. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350:2239-46.
3. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Prostate-cancer mortality at 11 years of followup. N Engl J Med 2012;366:981-90.
4. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
5. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005;23:8165-9.
6. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate- cancer screening trial. N Engl J Med 2009;360:1310-9.
7. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
8. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 2012;104:125-32.
9. Sandblom G, Varenhorst E, Rosell J, Lofman O, Carlsson P. Randomised prostate cancer screening trial: 20 year follow-up. BMJ 2011;342:d1539.
10. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725-32.
11. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374-83.
12. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78.
13. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intentupdate 2013. Eur Urol 2014;65:124-37.
14. Klotz L. Active surveillance for prostate cancer: a review. Curr Urol Rep 2010;11:165-71.
15. Krakowsky Y, Loblaw A, Klotz L. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. J Urol 2010;184:131-5.
16. Al Otaibi M, Ross P, Fahmy N, Jeyaganth S, Trottier H, Sircar K, et al. Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance. Cancer 2008;113:286-92.
17. Ross AE, Loeb S, Landis P, Partin AW, Epstein JI, Kettermann A, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010;28:2810-6.
18. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
19. Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998;160(6 Pt 2):2407-11.
20. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71(3 Suppl):933-8.
21. Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RC, Hoedemaeker RF, van Leenders GJ, et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011;185:121-5.
22. Kane CJ, Im R, Amling CL, Presti JC Jr, Aronson WJ, Terris MK, et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology 2010;76:695-700.
23. Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, et al. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 2011;60:291-303.
24. Cohen MS, Hanley RS, Kurteva T, Ruthazer R, Silverman ML, Sorcini A, et al. Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. Eur Urol 2008;54:371-81.
25. Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, Lattouf JB, et al. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men. Eur Urol 2008;54:1306-13.
26. Bastian PJ, Mangold LA, Epstein JI, Partin AW. Characteristics of insignificant clinical T1c prostate tumors: a contemporary analysis. Cancer 2004;101:2001-5.
27. Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009; 55:1321-30.
28. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, Partin AW, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011;29:2185-90.
29. Adamy A, Yee DS, Matsushita K, Maschino A, Cronin A, Vickers A, et al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol 2011;185:477-82.
30. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, et al. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol 2011;185:1656-60.
31. van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009;55:1-8.
32. Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M. Careful selection and close monitoring of lowrisk prostate cancer patients on active surveillance minimizes the need for treatment. Eur Urol 2010;58:831-5.
33. Kakehi Y, Kamoto T, Shiraishi T, Ogawa O, Suzukamo Y, Fukuhara S, et al. Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol 2008;38:122-8.
34. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126-31.
35. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, et al. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer 2008;112: 2664-70.
36. Ha JY, Kim BH, Park CH, Kim CI. Early experience with active surveillance in low-risk prostate cancer treated. Korean J Urol 2014;55:167-71.
37. Byun SS, Lee S, Lee SE, Lee E, Seo SI, Lee HM, et al. Recent changes in the clinicopathologic features of Korean men with prostate cancer: a comparison with Western populations. Yonsei Med J 2012;53:543-9.
38. Kim TH, Jeon HG, Choo SH, Jeong BC, Seo SI, Jeon SS, et al. Pathological upgrading and upstaging of patients eligible for active surveillance according to currently used protocols. Int J Urol 2014;21:377-81.
39. Choo SH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Choi HY, et al. Predictive factors of unfavorable prostate cancer in patients who underwent prostatectomy but eligible for active surveillance. Prostate Int 2014;2:70-5.
40. Iremashvili V, Pelaez L, Manoharan M, Jorda M, Rosenberg DL, Soloway MS. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols. Eur Urol 2012;62:462-8.
41. Sugimoto M, Shiraishi T, Tsunemori H, Demura T, Saito Y, Kamoto T, et al. Pathological findings at radical prostatectomy in Japanese prospective active surveillance cohort. Jpn J Clin Oncol 2010;40:973-9.
42. Mufarrij P, Sankin A, Godoy G, Lepor H. Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy. Urology 2010;76:689-92.
43. Goto Y, Nozumi K, Miyazaki K, Matsumoto A, Inoue A, Kito H, et al. Active surveillance criteria for prostate cancer: can they be applied to Japanese patients? Int J Urol 2012;19:163-6.
44. Lee DH, Jung HB, Lee SH, Rha KH, Choi YD, Hong SJ, et al. Comparison of pathological outcomes of active surveillance candidates who underwent radical prostatectomy using contemporary protocols at a high-volume Korean center. Jpn J Clin Oncol 2012;42:1079-85.
45. Lim SK, Kim KH, Shin TY, Chung BH, Hong SJ, Choi YD, et al. Yonsei criteria: a new protocol for active surveillance in the era of robotic and local ablative surgeries. Clin Genitourin Cancer 2013;11:501-7.
46. Jin BS, Kang SH, Kim DY, Oh HG, Kim CI, Moon GH, et al. Pathological upgrading in prostate cancer patients eligible for active surveillance: does prostate-specific antigen density matter? Korean J Urol 2015;56:624-9.
47. Kim TH, Jeong JY, Lee SW, Kim CK, Park BK, Sung HH, et al. Diffusion-weighted magnetic resonance imaging for prediction of insignificant prostate cancer in potential candidates for active surveillance. Eur Radiol 2015;25:1786-92.
48. Jeong CW, Park YH, Hwang SI, Lee S, Jeong SJ, Hong SK, et al. The role of 3-tesla diffusion-weighted magnetic resonance imaging in selecting prostate cancer patients for active surveillance. Prostate Int 2014;2:169-75.
49. Bonekamp D, Bonekamp S, Mullins JK, Epstein JI, Carter HB, Macura KJ. Multiparametric magnetic resonance imaging characterization of prostate lesions in the active surveillance population: incremental value of magnetic resonance imaging for prediction of disease reclassification. J Comput Assist Tomogr 2013;37:948-56.
50. Mullins JK, Bonekamp D, Landis P, Begum H, Partin AW, Epstein JI, et al. Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. BJU Int 2013;111:1037-45.
51. Park BH, Jeon HG, Choo SH, Jeong BC, Seo SI, Jeon SS, et al. Role of multiparametric 3.0-Tesla magnetic resonance imaging in patients with prostate cancer eligible for active surveillance. BJU Int 2014;113:864-70.
52. Lee DH, Koo KC, Lee SH, Rha KH, Choi YD, Hong SJ, et al. Tumor lesion diameter on diffusion weighted magnetic resonance imaging could help predict insignificant prostate cancer in patients eligible for active surveillance: preliminary analysis. J Urol 2013;190:1213-7.
53. Feliciano J, Teper E, Ferrandino M, Macchia RJ, Blank W, Grunberger I, et al. The incidence of fluoroquinolone resistant infections after prostate biopsy: are fluoroquinolones still effective prophylaxis? J Urol 2008;179:952-5.
54. Fujita K, Landis P, McNeil BK, Pavlovich CP. Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 2009;182:2664-9.